# US 2020/0390865 A1 · Fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390865 A1
- Document ID: US20200390865A1
- Status: Published application
- Kind: A1
- Application number: 16/893,498
- Filed: 2020-06-05
- Published: 2020-12-17
- Earliest claimed: 2015-05-07
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: David Bruce Baldwin; John Michael Beals; Jonathan Wesley Day; Craig Duane Dickinson; Andrew Ihor Korytko; Gregory Alan Lazar
- Web page: https://patentgrep.com/patent/US20200390865A1

## CPC

- A61K 38/28: Insulins
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/26: Glucagons
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- C07K 14/001: {by chemical synthesis}
- C07K 14/62: Insulins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of treating a patient with diabetes mellitus comprising administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising:
a) an insulin receptor agonist having the general formula Z1—Z2—Z3, wherein:
i) Z1 is an insulin B-chain analog, comprising the amino acid sequence:
X1X2X3QHLCGSHLVEALX4LVCGERGFX5YX6X7X8X9
wherein X1 is F, Q or A; X2 is V or G; X3 is N, K, D, G, Q, A or E; X4 is E, Y, Q, or H; X5 is H or F; X6 is G, T, S, H, V or is absent X7 is G, E, P, K, D, S, H or is absent; X8 is G, E, K, P, Q, D, H or is absent X9 is G, T, S, E, K, A or is absent, provided that the insulin B-chain analog includes at least one modification from the amino acid sequence of the B-chain of a molecule of human insulin at X4, X5, X6, X7, X8, or X9 (SEQ ID NO:1);
ii) Z2 is a first peptide linker comprising 5 to 10 amino acids, wherein at least 5 of said amino acids are G residues; and
iii) Z3 is an insulin A-chain analog comprising the amino acid sequence:
GIVEQCCTSX1CSLX2QLENYCX3X4
wherein X1 is T or I; X2 is D, Y, Q or E; X3 is G, N, S or A; and X4 is any naturally occurring amino acid, or is absent, provided that if X3 is N, then X4 must be an amino acid other than G or N (SEQ ID NO:2);
b) a second peptide linker; and
c) a human IgG Fc region;
wherein the C-terminal residue of the insulin receptor agonist is directly fused to the N-terminal residue of the second peptide linker, and the C-terminal residue of the second peptide linker is directly fused to the N-terminal residue of the human IgG Fc region.

### Claim 24 (depends on 23)

The method of claim 23, wherein the fusion protein is administered in combination with a GLP-1R agonist.

### Claim 25 (depends on 24)

The method of claim 24, wherein the GLP-1R agonist is dulaglutide.

### Claim 26

(canceled)
